Dermatomyositis Recruiting Phase 2 Trials for Tocilizumab (DB06273)

Also known as: Dermatomyositides / Dermatopolymyositis, unspecified

IndicationStatusPhase
DBCOND0002234 (Dermatomyositis)Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02043548Tocilizumab in the Treatment of Refractory Polymyositis and DermatomyositisTreatment